Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine in Amyotrophic Lateral Sclerosis
NCT00070993Phase 2Completed
- Sponsor
- National Center for Complementary and Integrative Health
- Start
- Dec 2002
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Creatine with Placebo (2 arms). Primary endpoint: Quantitative Muscle Testing at 9 months. Started Dec 2002; status: completed.
02
Drugs
creatine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00070993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070993.